↓ Skip to main content
What is this page? Embed badge

Non-Hodgkin Lymphoma

Overview of attention for book
Cover of 'Non-Hodgkin Lymphoma'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Epidemiology and Etiology of Non-Hodgkin Lymphoma
  3. Altmetric Badge
    Chapter 2 Pathology of B-Cell Lymphomas: Diagnosis and Biomarker Discovery
  4. Altmetric Badge
    Chapter 3 Pathology of T-Cell Lymphomas: Diagnosis and Biomarker Discovery
  5. Altmetric Badge
    Chapter 4 Gene expression profiling in non-hodgkin lymphomas.
  6. Altmetric Badge
    Chapter 5 Imaging of non-hodgkin lymphomas: diagnosis and response-adapted strategies.
  7. Altmetric Badge
    Chapter 6 Prognosis and Therapy of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
  8. Altmetric Badge
    Chapter 7 Biology, Prognosis, and Therapy of Waldenström Macroglobulinemia
  9. Altmetric Badge
    Chapter 8 Current therapeutic strategies and new treatment paradigms for follicular lymphoma.
  10. Altmetric Badge
    Chapter 9 Management of the marginal zone lymphomas.
  11. Altmetric Badge
    Chapter 10 Treatment Strategies in Mantle Cell Lymphoma
  12. Altmetric Badge
    Chapter 11 Management of Diffuse Large B-Cell Lymphoma (DLBCL)
  13. Altmetric Badge
    Chapter 12 Current management of peripheral T-cell lymphomas.
  14. Altmetric Badge
    Chapter 13 Post-transplant Lymphoproliferative Disorders.
  15. Altmetric Badge
    Chapter 14 Allogeneic Hematopoietic Cell Transplantation in Non-Hodgkin’s Lymphomas
Attention for Chapter 12: Current management of peripheral T-cell lymphomas.
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
8 Mendeley
Summary X Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Current management of peripheral T-cell lymphomas.
Chapter number 12
Book title
Non-Hodgkin Lymphoma
Published in
Cancer treatment and research, January 2015
DOI 10.1007/978-3-319-13150-4_12
Pubmed ID
25655615
Book ISBNs
978-3-31-913149-8, 978-3-31-913150-4
Authors

M Gooptu, R Rhoades, B Pro, M. Gooptu, R. Rhoades, B. Pro, Gooptu, M., Rhoades, R., Pro, B.

Abstract

Peripheral T-cell lymphomas (PTCLs) are an uncommon group of lymphoproliferative disorders accounting for approximately 10-15 % of all non-Hodgkin lymphomas (NHL) in Western countries. Although PTCLs are associated with poor prognosis, outcomes vary with disease subtype. The standard of care has been anthracycline-based induction combination chemotherapy, however, with the exception of low-risk ALK-positive anaplastic large cell lymphoma, relapse rates are high. Therefore, consolidation with autologous stem cell transplantation is usually recommended for patients deemed candidates, and with aggressive subtypes. In recent years, a number of novel agents including pralatrexate, histone deacetylase inhibitors, immunotoxins, proteasome inhibitors, aurora kinase inhibitors and the CD30 antibody-drug conjugate brentuximab vedotin, have shown promise in the treatment of PTCLs. Studies are underway to explore the activity of these newer agents used in the frontline setting.

View on publisher site
X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
 Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 3 38%
Student > Bachelor 1 13%
Other 1 13%
Student > Ph. D. Student 1 13%
Researcher 1 13%
Other 0 0%
Unknown 1 13%
Readers by discipline Count As %
Medicine and Dentistry 3 38%
Agricultural and Biological Sciences 1 13%
Biochemistry, Genetics and Molecular Biology 1 13%
Immunology and Microbiology 1 13%
Chemistry 1 13%
Other 0 0%
Unknown 1 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 February 2015.
All research outputs
#18,397,250
of 22,787,797 outputs
Outputs from Cancer treatment and research
#124
of 165 outputs
Outputs of similar age
#255,720
of 352,983 outputs
Outputs of similar age from Cancer treatment and research
#15
of 17 outputs
Altmetric has tracked 22,787,797 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 165 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,983 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.

This page is provided by Altmetric.